Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be 50 years of age or older, of either sex, and of any race/ethnicity.~* Subject must have a clinical history of ragweed-induced allergic rhinoconjunctivitis with or without asthma.~* Subject must have a positive skin prick test response to Ambrosia artemisiifolia at the Screening Visit~* Subject must have a forced expiratory volume in 1 second (FEV1) of at least 70% of predicted value at the Screening Visit and at Randomization.~* A subject's clinical laboratory tests, electrocardiogram (ECG) and vital signs conducted at the Screening Visit must be within normal limits or clinically acceptable to the investigator.~Exclusion Criteria:~* Subject with asthma who requires inhaled corticosteroids for the treatment of their asthma during the study period.~* Subject requiring anti-allergy medications during the time period from randomization to study completion.~* Subject who has received an immunosuppressive treatment within 3 months prior to the Screening Visit (except steroids for allergic and asthma symptoms).~* Subject with a history of anaphylaxis with cardiorespiratory symptoms.~* Subject with a history of chronic urticaria or angioedema.~* Subject with current severe atopic dermatitis.~* Female subject who is breastfeeding, pregnant, or intending to become pregnant.~* Subject with a history of allergy, hypersensitivity or intolerance to the ingredients of the investigational medicinal products (IMPs) (except for Ambrosia artemisiifolia), or self-injectable epinephrine.~* Subject with a history of self-injectable epinephrine use.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablet sublingual, once daily
- SCH 39641 6 Amb a 1-U (Type: EXPERIMENTAL): 6 Units Short Ragweed (Ambrosia artemisiifolia) Major Allergen 1 (Amb a 1-U) in an AIT, sublingual, once daily
- SCH 39641 12 Amb a 1-U (Type: EXPERIMENTAL): 12 Amb a 1-U in an AIT, sublingual, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).